Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug:34:101690.
doi: 10.1016/j.tranon.2023.101690. Epub 2023 May 16.

Detection of circulating tumor-derived material in peripheral blood of pediatric sarcoma patients: A systematic review

Eva Kristine Ruud Kjær  1 , Christian Bach Vase  1 , Maria Rossing  2 , Lise Barlebo Ahlborn  3 , Lisa Lyngsie Hjalgrim  4
Affiliations

Detection of circulating tumor-derived material in peripheral blood of pediatric sarcoma patients: A systematic review

Eva Kristine Ruud Kjær et al. Transl Oncol. 2023 Aug.

Abstract

Background: Detection of circulating tumor-derived material (cTM) in the peripheral blood (PB) of cancer patients has been shown to be useful in early diagnosis, prediction of prognosis, and disease monitoring. However, it has not yet been thoroughly evaluated for pediatric sarcoma patients.

Methods: We searched the PubMed and EMBASE databases for studies reporting the detection of circulating tumor cells, circulating tumor DNA, and circulating RNA in PB of pediatric sarcoma patients. Data on performance in identifying cTM and its applicability in diagnosis, and evaluation of tumor characteristics, prognostic factors, and treatment response was extracted from publications.

Results: A total of 79 studies were assigned for the present systematic review, including detection of circulating tumor cells (116 patients), circulating tumor DNA (716 patients), and circulating RNA (2887 patients). Circulating tumor cells were detected in 76% of patients. Circulating DNA was detected in 63% by targeted NGS, 66% by shallow WGS, and 79% by digital droplet PCR. Circulating RNA was detected in 37% of patients.

Conclusion: Of the cTM from Ewing's sarcoma and rhabdomyosarcoma ctDNA proved to be the best target for clinical application including diagnosis, tumor characterization, prognosis, and monitoring of disease progression and treatment response. For osteosarcoma the most promising targets are copy number alterations or patient specific micro RNAs, however, further investigations are needed to obtain consensus on clinical utility.

Keywords: CTC; Ewing's sarcoma; Osteosarcoma; Rhabdomyosarcoma; ctDNA; ctRNA.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper

Figures

Fig 1
Fig. 1
PRISMA flowchart.
Fig 2
Fig. 2
Overview of circulating tumor-derived material and its clinical application CTC: Circulating tumor cells; ctDNA: Circulating tumor DNA; ctRNA: Circulating tumor RNA; ES: Ewing's sarcoma; EV: Extracellular vesicle; ddPCR: Digital droplet polymerase chain reaction; FCM: Flow cytometry; MF: Microfiltration; miRNA: MicroRNA; NGS: Next generation sequencing; qRT-PCR: Quantitative reverse transcription polymerase chain reaction; RT-PCR: Reverse transcription polymerase chain reaction; TLDA: TaqMan low density array. Created with BioRender.com.
See this image and copyright information in PMC

References

    1. Steliarova-Foucher E., et al. International incidence of childhood cancer, 2001–10: a population-based registry study. Lancet Oncol. 2017;18:719–731. - PMC - PubMed
    1. Ward E., Desantis C., Robbins, Anthony Kohler B., Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J. Clin. 2014;64:83–103. - PubMed
    1. Tirode F., et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov. 2014;4:1342–1353. - PMC - PubMed
    1. Berner K., et al. Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma. Acta Oncol. (Madr). 2015;54:25–33. - PMC - PubMed
    1. Oberlin O., et al. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: Long-term results from the International Society of Pediatr. J. Clin. Oncol. 2012;30:2457–2465. - PubMed